Jefferies analyst Michael Yee says three upcoming legal and regulatory decisions around Enbrel, Neulasta, and Sensipar could cause potential "headline downside risk" for Amgen shares. However, these are "manageable or somewhat expected," Yee tells investors in a research note. He points out that Amgen has a $10B Dutch Tender underway and an additional $4B buyback authorization. The stock looks "very attractive" at current levels, and Amgen has "significant capital deployment and M&A capabilities," Yee contends. He keeps a Buy rating on the stock with a $200 price target.